Home > Insider Trading > Filing (0001181431-12-042070)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544116	Durata Therapeutics Inc.	DRTX	Pharmaceutical Preparations (2834)	871247903

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1245624	James Healy	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	Yes	No	Yes	No
1362314	Eric Buatois	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1380734	P L Vii Partners Venture Sofinnova	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1421501	Sofinnova Management Vii, L.l.c.	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-24	1,683,094	$0.00	1,683,094	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2012-07-24	588,236	$9.00	2,271,330	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-07-24	1,683,094	$0.00	1,683,094	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,250	Direct

Footnotes

All outstanding shares of the Issuer's Series A Preferred Stock, including the 13,464,758 shares held by the Reporting Persons, were automatically converted into Common Stock on a 1-for-0.125 basis upon the closing of the Issuer's initial public offering for no additional consideration.
Shares are owned directly by Sofinnova Venture Partners VII, L.P. ("SV VII"). Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of SV VII, and James Healy, a director of the Issuer, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, may be deemed to have shared voting and dispositive power over the shares owned by SV VII . Such persons and entities disclaim beneficial ownership over the shares owned by SV VII except to the extent of any pecuniary interest therein.
The shares were purchased in the Issuer's initial public offering.
The shares are owned directly by Mr. Healy.